Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
02 Agosto 2023 - 8:00AM
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a
clinical-stage biopharmaceutical company focused on redefining the
intracellular delivery of nucleic acids and small molecules with
its lipid nanocrystal (LNC) platform technology, announces that
Jerome D. Jabbour, Chief Executive Officer, will hold meetings with
institutional investors during the BTIG Virtual Biotechnology
Conference 2023 being held August 7-8, 2023. The Matinas
presentation is posted on the Investors page of the Company’s
website.
Institutional investors interested in arranging
a meeting with Matinas BioPharma management should contact the BTIG
conference coordinator or Jody Cain at LHA investor relations at
jcain@lhai.com.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology to maximize global clinical impact and patient
access.
Matinas’ lead LNC-based therapy is MAT2203, an
oral formulation of the broad-spectrum antifungal drug amphotericin
B, which although highly potent, can be associated with significant
toxicity. Matinas’ LNC platform provides oral delivery of
amphotericin B without the significant nephrotoxicity otherwise
associated with IV-delivered formulations. MAT2203 also allows for
safe, longer-term use outside of a hospital setting, which could
have substantial favorable pharmacoeconomic impact. MAT2203
successfully completed the Phase 2 EnACT program in cryptococcal
meningitis, meeting its primary endpoint and achieving robust
survival. MAT2203 is being positioned for a single pivotal Phase 3
study in the treatment of aspergillosis and other invasive fungal
infections, including mucormycosis, c. auris and other candidiasis,
and certain endemic mycoses.
In addition to MAT2203, preclinical and clinical
data have demonstrated that this novel technology can provide
solutions to many of the challenges standing in the way of
achieving safe and effective intracellular delivery of both small
molecules and larger, more complex molecular cargos such as siRNA,
antisense oligonucleotides, and vaccines. The combination of its
unique mechanism of action and flexibility with routes of
administration (including oral) positions Matinas’ LNC technology
to potentially become a preferred next-generation intracellular
drug delivery platform. For more information, please visit
www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
our collaboration with National Resilience, Inc., the potential of
our LNC platform and PS-NP delivery technologies, and the future
development of its product candidates, the Company’s ability to
identify and pursue development, licensing and partnership
opportunities for its products or platform delivery technologies on
favorable terms, if at all, and the ability to obtain required
regulatory approval and other statements that are predictive in
nature, that depend upon or refer to future events or conditions.
All statements other than statements of historical fact are
statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor Contact
LHA Investor RelationsJody
CainJcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Matinas Biopharma (AMEX:MTNB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024